Gastric cancer (GC) is the second most common cause of cancer-related deaths in the world. This study aims to investigate the differential tissue expression of ppGalNAc- T15 and to evaluate its possible association with clinical-pathological parameters and outcome of gastric adenocarcinoma patients. For these 70 patients were evaluated the expression by immunohistochemistry to ppGalNAc-T15. Our results showed that 33 (47.1%) patients were ppGalNAc-T15+ positive and 37 (52.9%) negative. Positive staining for ppGalNAc-T15 was significantly present in patients older than 60 years (P= 0.0306) and submitted to total gastrectomy (P=0.0087). Also, some results remained at the limit of significance as surgical standing (P = 0.0562) and histological grade (P=0.0549). Therefore, the ppGalNAc-T15 immunoreactivity can be useful to understand the prognosis of patients with gastric cancer.
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. www.journals.viamedica.pl/folia_histochemica_cytobiologica ©Polish Society for Histochemistry and Cytochemistry Folia Histochem Cytobiol.
The identification of novel biomarkers for diagnosis and prognosis of Gastric Cancer (GC) is pivotal to reduce disease-associated mortality. Previous studies have reported that Siglec-15 is overexpressed on human cancer, including colon, thyroid, lung, liver. The Siglecs are a group of sialic-acid-binding immunoglobulin-like lectins, involved in cell-cell and cell-pathogen interactions. Recently, it was reported that Siglec-15 could be a potential target for cancer immunotherapy, because it supresses T cell activity and its expression with PD-L1 are mutually exclusive. However, the relationship between the expression of Siglec-15 in GC pathological and outcome parameters were not investigated. Therefore, the purpose of this study was to evaluate the expression of SIGLEG15 in gastric adenocarcinomas patients and correlated the expression patterns with each other and with some clinicopathological variables. Surgical specimens of GC tissue and adjacent normal mucosa obtained from 67 patients were examined. The patients underwent gastrectomy at the Hospital do Cancer de Pernambuco, Brazil, between 2013 and 2016. Informed consent was obtained from each patient, with all protocols approved by the ethics committee's (CAAE: 39976214.90000.5205). Protein expression was examined by immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) specimens. The primary anti-SIGLEC15 antibody were used and positive control was performed on a tissue model indicated on the data sheet and reference sources (The Human Protein Atlas). Samples that demonstrated enzyme staining in more than 10% of the neoplastic cells in different degrees of intensity were considered positive and those that did not present were negative. Of 67 GC patients, 52 (77.61%) were SIGLEC-15 positive and 15 patients (25.38%) were negative. In 40 samples (59.70%) of the 67 patients analysed presented an adjacent normal tissue, in which 14 (35%) were SIGLEC-15 positive, specially in productions cells of the gastric glands and in the ducts. In neoplastic lesions, SIGLEC-15 was observed in the cytoplasm in 13 samples (19.40%), perinuclear in 4 (5.97%) and nuclear in 1 only sample (1.49%). On the other hand, combinations of cytoplasmic, nuclear and perinuclear staining were observed in 44 samples (61.9%). Expression of SIGLEC-15 was significantly associated with age (p=0.047), with tumor differentiation (p=0.002), angiolymphatic invasion (p=0.02) and surgical staging (p=0.056). Additional analysis, including sex, type of surgery, initial treatment, nodal status, radiotherapy, chemotherapy, lymph node, H.Pylory infection and overall and disease-free survival were not significant. High Siglec-15 expression in gastric cancer could be a novel biomarker for surgical staging and vascular invasion. Further studies with a larger group of patients and experimental assays are required to elucidate Siglec-15 role in gastric cancer. Citation Format: Michelly Cristiny Pereira, Michael Williames Quirino, Antônio Felix Silva Filho, Mário Rino Martins, Maira Galdino da Rocha Pitta, Moacyr Jesus Barreto de Melo Rego. Clinical Association of Siclec15 in gastric adenocarcinomas patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6481.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.